Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 24 Apr 24 424B3 Prospectus supplement
- 23 Apr 24 EFFECT Notice of effectiveness
- 18 Apr 24 POS AM Prospectus update (post-effective amendment)
- 30 Nov 23 424B3 Prospectus supplement
- 30 Nov 23 EFFECT Notice of effectiveness
- 29 Nov 23 POS AM Prospectus update (post-effective amendment)
- 23 Oct 23 424B3 Prospectus supplement
- 11 Aug 23 424B3 Prospectus supplement
- 11 Aug 23 EFFECT Notice of effectiveness
- 10 Aug 23 POS AM Prospectus update (post-effective amendment)
- 5 Jun 23 EFFECT Notice of effectiveness
- 2 Jun 23 424B3 Prospectus supplement
- 1 Jun 23 F-1/A Registration statement (foreign) (amended)
- 11 May 23 F-1/A Registration statement (foreign) (amended)
-
3 May 23 F-1 Registration statement (foreign)
ADXN similar filings
Filing view
External links
Exhibit 23.3
Consent of Independent Registered Public Accounting Firm
Addex Therapeutics Ltd
Geneva, Switzerland
We hereby consent to the incorporation by reference in the Prospectus constituting a part of this Registration Statement of our report dated March 30, 2023, relating to the consolidated financial statements of Addex Therapeutics Ltd appearing in the Company’s Annual Report on Form 20-F for the year ended December 31, 2022. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern
We also consent to the reference to us under the caption “Experts” in the Prospectus.
/s/ BDO AG
/s/ Christoph Tschumi | /s/ Nigel Le Masurier |
Zurich, May 3, 2023